Stephens Inc. AR Buys New Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Stephens Inc. AR bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,717 shares of the biopharmaceutical company’s stock, valued at approximately $101,000.

Other large investors have also recently added to or reduced their stakes in the company. Hazlett Burt & Watson Inc. increased its position in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Amicus Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the period. OLD Second National Bank of Aurora acquired a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $26,000. AlphaCentric Advisors LLC increased its position in shares of Amicus Therapeutics by 1.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company’s stock valued at $2,189,000 after purchasing an additional 2,500 shares during the period. Finally, Blue Trust Inc. increased its position in shares of Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the period.

Analyst Ratings Changes

FOLD has been the topic of several research analyst reports. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Stock Performance

FOLD opened at $9.77 on Monday. The firm has a market cap of $2.92 billion, a PE ratio of -28.74, a P/E/G ratio of 1.69 and a beta of 0.61. The business has a fifty day simple moving average of $9.60 and a 200-day simple moving average of $10.43. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a fifty-two week low of $8.78 and a fifty-two week high of $14.03.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.